Abstract
Liquid biopsy refers to the molecular analysis of components obtained from body fluids, including blood, urine, and cerebrospinal fluids. Liquid biopsy tests extend to cover the genetic and epigenetic analysis of cell-free DNA, circulating miRNA, as well as extracellular vesicles components. Liquid biopsy showed utility as a noninvasive source of biomarkers for cancer diagnosis and monitoring of disease response. The study of liquid biopsy has recently extended to encompass other pathologies, including neurodegenerative diseases. The absence of biomarkers for early detection of neurodegenerative diseases and the consequent delay in therapy is detrimental. Liquid biopsy represents a step toward the discovery of an effective biomarker for neurodegeneration. This chapter presents an overview of the application of liquid biopsy as a potential biomarker for three of the most common neurodegenerative disease, i.e., Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS).
This is a preview of subscription content, log in via an institution to check access.
References
Abeysinghe AADT, Deshapriya RDUS, Udawatte C (2020) Alzheimer’s disease; a review of the pathophysiological basis and therapeutic interventions. Life Sci. https://doi.org/10.1016/j.lfs.2020.117996. Elsevier Inc
Al-Chalabi A et al (2016) Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol 15:1182–1194. https://doi.org/10.1016/S1474-4422(16)30199-5. Lancet Publishing Group
Banack SA, Dunlop RA, Cox PA (2020) An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral sclerosis/motor neuron disease. Open Biol 10(6). https://doi.org/10.1098/rsob.200116
Banks WA et al (2021) Healthy aging and the blood–brain barrier. Nat Aging 1:243–254. https://doi.org/10.1038/s43587-021-00043-5. Springer
Beach TG et al (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol 71(4):266–273. https://doi.org/10.1097/NEN.0b013e31824b211b
Begcevic I et al (2018) Brain-related proteins as potential CSF biomarkers of Alzheimer’s disease: a targeted mass spectrometry approach. J Proteome 182:12–20. https://doi.org/10.1016/j.jprot.2018.04.027
Bieri G, Gitler AD, Brahic M (2018) Internalization, axonal transport and release of fibrillar forms of alpha-synuclein. Neurobiol Dis 109:219–225. https://doi.org/10.1016/j.nbd.2017.03.007. Academic Press Inc
Brooks BR et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 1(5):293–299. https://doi.org/10.1080/146608200300079536
Caggiano C et al (2021) Comprehensive cell type decomposition of circulating cell-free DNA with CelFiE. Nat Commun 12(1). https://doi.org/10.1038/s41467-021-22901-x
Calvani R et al (2020) A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson’s disease in older people: an EXosomes in PArkiNson Disease (EXPAND) ancillary study. GeroScience 42(5):1323–1334. https://doi.org/10.1007/s11357-020-00192-2
Cao Z et al (2019) α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson’s disease. Neurosci Lett 696:114–120. https://doi.org/10.1016/j.neulet.2018.12.030
Capri M et al (2015) MARK-AGE population: from the human model to new insights. Mech Ageing Dev 151:13–17. https://doi.org/10.1016/j.mad.2015.03.010
Cardoso AL et al (2012) miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology 135(1):73–88. https://doi.org/10.1111/j.1365-2567.2011.03514.x
Cassinelli Petersen G et al (2022) Overview of tau PET molecular imaging. Curr Opin Neurol 35:230–239. https://doi.org/10.1097/WCO.0000000000001035. Lippincott Williams and Wilkins
Castagné R et al (2018) Allostatic load and subsequent all-cause mortality: which biological markers drive the relationship? Findings from a UK birth cohort. Eur J Epidemiol 33(5):441–458. https://doi.org/10.1007/s10654-018-0364-1
Cellura E et al (2012) Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg 114(6):550–554. https://doi.org/10.1016/j.clineuro.2011.11.026
Cerri S et al (2018) The exosomal/total α-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients. Front Cell Neurosci 12. https://doi.org/10.3389/fncel.2018.00125
Chen JF et al (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38(2):228–233. https://doi.org/10.1038/ng1725
Cheng L et al (2014) Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles 3(1). https://doi.org/10.3402/jev.v3.23743
Chim SSC, Tong YK, Chiu RWK, Lau TK, Leung TN, Chan LYS, Oudejans CBM, Ding C, Lo YMD (2005) Detection of the placental epigenetic signature of the MASPIN gene in maternal plasma. Proc Natl Acad Sci USA 102:14753–14758
Cho KHT et al (2019) Emerging roles of miRNAs in brain development and perinatal brain injury. Front Physiol 10. https://doi.org/10.3389/fphys.2019.00227
Cogswell JP et al (2008) Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14(1):27–41. https://doi.org/10.3233/JAD-2008-14103
Counts SE et al (2017) Biomarkers for the early detection and progression of Alzheimer’s disease. Neurotherapeutics 14:35–53. https://doi.org/10.1007/s13311-016-0481-z. Springer New York LLC
Cummings J (2019) The National Institute on Aging – Alzheimer’s Association Framework on Alzheimer’s disease: application to clinical trials. Alzheimers Dement 15:172–178. https://doi.org/10.1016/j.jalz.2018.05.006. Elsevier Inc
Danzer KM et al (2009) Seeding induced by α-synuclein oligomers provides evidence for spreading of α-synuclein pathology. J Neurochem 111(1):192–203. https://doi.org/10.1111/j.1471-4159.2009.06324.x
Delay C, Mandemakers W, Hébert SS (2012) MicroRNAs in Alzheimer’s disease. Neurobiol Dis 46:285–290. https://doi.org/10.1016/j.nbd.2012.01.003
DeMaagd G, Philip A (2015) Parkinson’s disease and its management part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P T 40(8):504–532. http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4517533/. Accessed 30 May 2023
Di Maio R et al (2018) LRRK2 activation in idiopathic Parkinson’s disease. Sci Transl Med 10(451). https://doi.org/10.1126/scitranslmed.aar5429
Doroszkiewicz J, Groblewska M, Mroczko B (2022) Molecular biomarkers and their implications for the early diagnosis of selected neurodegenerative diseases. Int J Mol Sci. https://doi.org/10.3390/ijms23094610. MDPI
Doyle LM, Wang MZ (2019) Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. https://doi.org/10.3390/cells8070727. MDPI
Dubois B et al (2016) Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12:292–323. https://doi.org/10.1016/j.jalz.2016.02.002. Elsevier Inc
Fernando MR et al (2017) New evidence that a large proportion of human blood plasma cell-free DNA is localized in exosomes. PLoS One 12(8). https://doi.org/10.1371/journal.pone.0183915
Fiandaca MS et al (2015) Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement 11(6):600–607.e1. https://doi.org/10.1016/j.jalz.2014.06.008
Frost S et al (2014) O3-13-01: retinal amyloid fluorescence imaging predicts cerebral amyloid burden and Alzheimer’s disease. Alzheimers Dement 10(4S_Part_4):P234–P235. https://doi.org/10.1016/j.jalz.2014.04.341
Gaitsch H, Franklin RJM, Reich DS (2022) Cell-free DNA-based liquid biopsies in neurology. Brain 146(5):1758. https://doi.org/10.1093/brain/awac438
Gitler AD, Dhillon P, Shorter J (2017) Neurodegenerative disease: models, mechanisms, and a new hope. DMM Dis Models Mech 10:499–502. https://doi.org/10.1242/dmm.030205. Company of Biologists Ltd
Goetzl EJ et al (2015) Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology 85(1):40–47. https://doi.org/10.1212/WNL.0000000000001702
Goldstein LH, Abrahams S (2013) Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol 12:368–380. https://doi.org/10.1016/S1474-4422(13)70026-7
Gong CX et al (2022) Multi-targets: an unconventional drug development strategy for Alzheimer’s disease. Front Aging Neurosci. https://doi.org/10.3389/fnagi.2022.837649. Frontiers Media S.A
Greening DW, Simpson RJ (2018) Understanding extracellular vesicle diversity–current status. Expert Rev Proteom 15:887–910. https://doi.org/10.1080/14789450.2018.1537788. Taylor and Francis Ltd
Guix FX et al (2018) Detection of aggregation-competent tau in neuron-derived extracellular vesicles. Int J Mol Sci 19(3). https://doi.org/10.3390/ijms19030663
Guo H et al (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466(7308):835–840. https://doi.org/10.1038/nature09267
Hampel H et al (2021) Future avenues for Alzheimer’s disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2020.108081. Elsevier Ltd
Han C et al (2019) Exosomes from patients with Parkinson’s disease are pathological in mice. J Mol Med 97(9):1329–1344. https://doi.org/10.1007/s00109-019-01810-z
Haque SS (2022) Biomarkers in the diagnosis of neurodegenerative diseases. RUDN J Med 26(4):431–440. https://doi.org/10.22363/2313-0245-2022-26-4-431-440
Harischandra DS et al (2019) Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein. Sci Signal 12(572). https://doi.org/10.1126/scisignal.aau4543
He R et al (2018) Recent advances in biomarkers for Parkinson’s disease. Front Aging Neurosci 10:305. https://doi.org/10.3389/fnagi.2018.00305. Frontiers Media S.A
Hughes AJ et al (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125(4):861–870. https://doi.org/10.1093/brain/awf080
Hunter CA et al (2015) Medical costs of Alzheimer’s disease misdiagnosis among US Medicare beneficiaries. Alzheimers Dement 11(8):887–895. https://doi.org/10.1016/j.jalz.2015.06.1889
Ismail K (2016) Development and utilization of Luminex biomarker assays or diagnosis and monitoring of neurodegenerative disease. Lancaster University (United Kingdom)
Johnston CA et al (2006) Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London [2]. J Neurol 253:1642–1643. https://doi.org/10.1007/s00415-006-0195-y
Katon W, Russo J, Gavin A (2014) Predictors of postpartum depression. J Women’s Health 23(9):753–759. https://doi.org/10.1089/jwh.2014.4824
Katsu M et al (2019) MicroRNA expression profiles of neuron-derived extracellular vesicles in plasma from patients with amyotrophic lateral sclerosis. Neurosci Lett 708. https://doi.org/10.1016/j.neulet.2019.03.048
Khoo SK et al (2012) Plasma-based circulating microRNA biomarkers for Parkinson’s disease. J Parkinsons Dis 2(4):321–331. https://doi.org/10.3233/JPD-012144
Kiernan MC et al (2011) Amyotrophic lateral sclerosis. Lancet 377:942–955. https://doi.org/10.1016/S0140-6736(10)61156-7. Elsevier B.V
Koval ED et al (2013) Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet 22(20):4127–4135. https://doi.org/10.1093/hmg/ddt261
Kulabukhova DG et al (2021) Plasma exosomes in inherited forms of Parkinson’s disease. Mol Biol 55(2):338–345. https://doi.org/10.31857/S0026898421010092
Kumar P et al (2013) Circulating miRNA biomarkers for Alzheimer’s disease. PLoS One 8(7). https://doi.org/10.1371/journal.pone.0069807
Lachenal G et al (2011) Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol Cell Neurosci 46(2):409–418. https://doi.org/10.1016/j.mcn.2010.11.004
Leblond CS et al (2014) Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp Neurol 262 Pt B:91–101. https://doi.org/10.1016/j.expneurol.2014.04.013. Academic Press Inc
Lee VMY, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121–1159. https://doi.org/10.1146/annurev.neuro.24.1.1121
Lee JH et al (2022) Faulty autolysosome acidification in Alzheimer’s disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques. Nat Neurosci 25(6):688–701. https://doi.org/10.1038/s41593-022-01084-8
Lim B et al (2019) Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer’s disease. Clin Chem Lab Med 57(12). https://doi.org/10.1515/cclm-2019-0428
Lindsay MA (2008) microRNAs and the immune response. Trends Immunol 29:343–351. https://doi.org/10.1016/j.it.2008.04.004
Lista S et al (2013) Blood and plasma-based proteomic biomarker research in Alzheimer’s disease. Prog Neurobiol 101–102:1–17. https://doi.org/10.1016/j.pneurobio.2012.06.007
Liu CG et al (2014) MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer’s disease. Int J Mol Med 34(1):160–166. https://doi.org/10.3892/ijmm.2014.1780
Lowes H et al (2020) Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment. Mol Neurodegener 15(1). https://doi.org/10.1186/s13024-020-00362-y
Luo H et al (2021) Liquid biopsy of methylation biomarkers in cell-free DNA. Trends Mol Med 27:482–500. https://doi.org/10.1016/j.molmed.2020.12.011. Elsevier Ltd
Magalhaes J et al (2016) Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum Mol Genet 25(16):3432–3445. https://doi.org/10.1093/hmg/ddw185
Magen I et al (2021) Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nat Neurosci 24(11):1534–1541. https://doi.org/10.1038/s41593-021-00936-z
Mahmood W et al (2020) Aging-associated distinctive DNA methylation changes of LINE-1 retrotransposons in pure cell-free DNA from human blood. Sci Rep. https://doi.org/10.1038/s41598-020-79126-z. Nature Research
Mendioroz M, Martínez‐Merino L, Blanco‐Luquin I, Urdánoz A, Roldán M, Jericó I (2018) Liquid biopsy: a new source of candidate biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 5(6):763–768
Miao Y et al (2015) A TRP channel senses lysosome neutralization by pathogens to trigger their expulsion. Cell 161(6):1306–1319. https://doi.org/10.1016/j.cell.2015.05.009
Moldovan L et al (2014) Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 18(3):371–390. https://doi.org/10.1111/jcmm.12236
Montagne A, Zhao Z, Zlokovic BV (2017) Alzheimer’s disease: a matter of blood-brain barrier dysfunction? J Exp Med 214:3151–3169. https://doi.org/10.1084/jem.20171406. Rockefeller University Press
Myszczynska MA et al (2020) Applications of machine learning to diagnosis and treatment of neurodegenerative diseases. Nat Rev Neurol 16:440–456. https://doi.org/10.1038/s41582-020-0377-8. Nature Research
Ngolab J et al (2017) Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology. Acta Neuropathol Commun 5(1):46. https://doi.org/10.1186/s40478-017-0445-5
Nichols E et al (2019) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(1):88–106. https://doi.org/10.1016/S1474-4422(18)30403-4
Niu M et al (2020) A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson’s disease development and progression. Eur J Neurol 27(6):967–974. https://doi.org/10.1111/ene.14208
O’Brien J et al (2018) Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. https://doi.org/10.3389/fendo.2018.00402. Frontiers Media S.A
Oliveira SR et al (2020) Circulating inflammatory mirnas associated with Parkinson’s disease pathophysiology. Biomol Ther 10(6):1–13. https://doi.org/10.3390/biom10060945
Ouyang YB et al (2012) MiR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion 12(2):213–219. https://doi.org/10.1016/j.mito.2011.09.001
Pacia CP et al (2020) Feasibility and safety of focused ultrasound-enabled liquid biopsy in the brain of a porcine model. Sci Rep 10(1). https://doi.org/10.1038/s41598-020-64440-3
Papadopoulos VE et al (2018) Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson’s disease. Hum Mol Genet 27(10):1696–1710. https://doi.org/10.1093/hmg/ddy075
Patil KS et al (2019) Combinatory microRNA serum signatures as classifiers of Parkinson’s disease. Parkinsonism Relat Disord 64:202–210. https://doi.org/10.1016/j.parkreldis.2019.04.010
Pegoraro V, Merico A, Angelini C (2019) MyomiRNAs dysregulation in ALS rehabilitation. Brain Sci 9(1). https://doi.org/10.3390/brainsci9010008
Penke B et al (2019) Key peptides and proteins in Alzheimer’s disease. Curr Protein Pept Sci 20(6):577–599. https://doi.org/10.2174/1389203720666190103123434
Peters OM, Ghasemi M, Brown RH (2015) Emerging mechanisms of molecular pathology in ALS. J Clin Investig 125:1767–1779. https://doi.org/10.1172/JCI71601. American Society for Clinical Investigation
Podlesniy P, Figueiro‐Silva J, Llado A, Antonell A, Sanchez‐Valle R, Alcolea D, … Trullas R (2013) Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann Neurol 74(5):655–668
Pyle A et al (2015) Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson’s disease. Ann Neurol 78(6):1000–1004. https://doi.org/10.1002/ana.24515
Quek C, Hill AF (2017) The role of extracellular vesicles in neurodegenerative diseases. Biochem Biophys Res Commun 483:1178–1186. https://doi.org/10.1016/j.bbrc.2016.09.090. Elsevier B.V
Raheja R et al (2018) Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve 58(2):261–269. https://doi.org/10.1002/mus.26106
Regev K et al (2016) Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurol Neuroimmunol NeuroInflamm 3(5). https://doi.org/10.1212/NXI.0000000000000267
Robichaud PP et al (2021) Circulating cell-free DNA as potential diagnostic tools for amyotrophic lateral sclerosis. Neurosci Lett 750. https://doi.org/10.1016/j.neulet.2021.135813
Ryan M et al (2019) Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol 76(11):1367–1374. https://doi.org/10.1001/jamaneurol.2019.2044
Saenz-Antoñanzas A et al (2019) Liquid biopsy in glioblastoma: opportunities, applications and challenges. Cancers. https://doi.org/10.3390/cancers11070950. MDPI AG
Saucier D et al (2019) Identification of a circulating miRNA signature in extracellular vesicles collected from amyotrophic lateral sclerosis patients. Brain Res 1708:100–108. https://doi.org/10.1016/j.brainres.2018.12.016
Soares Martins T et al (2021) Diagnostic and therapeutic potential of exosomes in Alzheimer’s disease. J Neurochem 156:162–181. https://doi.org/10.1111/jnc.15112. Blackwell Publishing Ltd
Soelter TM et al (2022) Nucleic acid liquid biopsies in Alzheimer’s disease: current state, challenges, and opportunities. Heliyon 8:e09239. https://doi.org/10.1016/j.heliyon.2022.e09239. Elsevier Ltd
Soliman R et al (2021) Assessment of diagnostic potential of some circulating microRNAs in amyotrophic lateral sclerosis patients, an Egyptian study. Clin Neurol Neurosurg 208. https://doi.org/10.1016/j.clineuro.2021.106883
Sørensen SS, Nygaard AB, Christensen T (2016) miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia – an exploratory study. Transl Neurodegener 5(1). https://doi.org/10.1186/s40035-016-0053-5
Stuendl A et al (2016) Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies. Brain 139(2):481–494. https://doi.org/10.1093/brain/awv346
Tang Y, Lutz MW, Xing Y (2019) A systems-based model of Alzheimer’s disease. Alzheimers Dement 15:168–171. https://doi.org/10.1016/j.jalz.2018.06.3058. Elsevier Inc
Tasca E et al (2016) Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS. Clin Neuropathol 35(1):22–30. https://doi.org/10.5414/NP300889
Toivonen JM et al (2014) MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS One 9(2). https://doi.org/10.1371/journal.pone.0089065
Townley-Tilson WHD, Callis TE, Wang D (2010) MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol 42:1252–1255. https://doi.org/10.1016/j.biocel.2009.03.002
Traynor BJ et al (2000) Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol 57(1):109–113. https://doi.org/10.1001/archneur.57.1.109
Turner MR et al (2009) Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 8:94–109. https://doi.org/10.1016/S1474-4422(08)70293-X. Elsevier
Vorobev SV et al (2022) Graphene as the basis of biological sensors for the diagnosis of neurodegenerative dementia. Russ Mil Med Acad Rep 41(4):421–428. https://doi.org/10.17816/rmmar111884
Wilkins HM et al (2016) Extracellular mitochondria and mitochondrial components act as damage-associated molecular pattern molecules in the mouse brain. J Neuroimmune Pharmacol 11(4):622–628. https://doi.org/10.1007/s11481-016-9704-7
Winblad B et al (2016) Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 15:455–532. https://doi.org/10.1016/S1474-4422(16)00062-4. Lancet Publishing Group
Xu Q, Cui Y et al (2018a) Exosomes from C2C12 myoblasts enhance osteogenic differentiation of MC3T3-E1 pre-osteoblasts by delivering miR-27a-3p. Biochem Biophys Res Commun 498(1):32–37. https://doi.org/10.1016/j.bbrc.2018.02.144
Xu Q, Zhao Y et al (2018b) Comparison of the extraction and determination of serum exosome and miRNA in serum and the detection of miR-27a-3p in serum exosome of ALS patients. Intractable Rare Dis Res 7(1):13–18. https://doi.org/10.5582/irdr.2017.01091
Yilmaz ŞG et al (2016) Hypothesis: do miRNAs targeting the leucine-rich repeat kinase 2 gene (LRRK2) influence Parkinson’s disease susceptibility? OMICS J Integr Biol 20(4):224–228. https://doi.org/10.1089/omi.2016.0040
Zampetaki A et al (2012) Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 93:555–562. https://doi.org/10.1093/cvr/cvr266
Zhao Y, Alexandrov PN, Lukiw WJ (2016) Anti-microRNAs as novel therapeutic agents in the clinical management of Alzheimer’s disease. Front Neurosci 10. https://doi.org/10.3389/fnins.2016.00059
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2023 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Youssef, S.H., Atalah, H.N., Badawy, M.T., El-Fawal, H.N., Salama, M.M. (2023). Three Neurodegenerative Diseases: A Single Hope. In: Mohamed, E. (eds) Handbook of Neurodegenerative Disorders . Springer, Singapore. https://doi.org/10.1007/978-981-19-3949-5_3-1
Download citation
DOI: https://doi.org/10.1007/978-981-19-3949-5_3-1
Received:
Accepted:
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-3949-5
Online ISBN: 978-981-19-3949-5
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences